NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET.
马里兰州贝尔茨维尔,2024年11月26日 (全球新闻网) -- NextCure, Inc. (纳斯达克: NXTC)是一家临床阶段的生物制药公司,致力于发现和开发新的、首创的和最佳的癌症治疗疗法,今天宣布将于12月5日星期四下午12:00在纽约市参加第36届派杰投资医疗大会的炉边聊天。
A live audio webcast will be available through the Investors section of the company's website at . A replay of the webcast will be available after the event and archived on the website for 30 days.
通过公司网站的投资者部分将提供实时音频网络直播,活动结束后,网络直播的录音将在网站上保存30天。
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.
关于NextCure, Inc.
NextCure是一家临床阶段的生物制药公司,专注于推进治疗癌症患者的创新药物,这些患者对目前的疗法没有反应或疾病进展,通过使用抗体药物偶联物、抗体和蛋白质等差异化的作用机制。我们专注于推进利用我们在理解生物途径和生物标志物、细胞之间的相互作用(包括在肿瘤微环境中)及每种相互作用在生物学反应中所起的作用方面的核心优势的治疗方法。
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
关于前瞻性声明的警示声明
本新闻稿中的观点而非历史事实的表述为前瞻性声明。诸如 "预期","相信","打算","希望","前进" 等表达旨在识别前瞻性声明。前瞻性声明涉及重大风险和不确定性,可能导致实际结果与任何前瞻性声明中预期的结果有实质性差异。此类风险和不确定性包括但不限于:我们有限的经营历史和无任何已获得商业销售批准的产品;我们巨额的亏损历史;我们需要获取额外融资;与临床发展相关的风险,包括早期临床数据可能得不到后续临床结果的证实;临床前研究结果可能得不到临床试验的证实;与市场批准和商业化相关的风险;以及nextcure对关键员工的依赖。更详细的关于这些以及可能影响nextcure实际结果的其他因素的信息,请参阅nextcure提交给美国证券交易委员会(“SEC”)的文件,包括nextcure最新的10-k表和随后的10-Q表。您不应过于依赖任何前瞻性声明。即使预期发生变化,nextcure也无义务更新任何前瞻性声明。
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
投资者查询
蒂莫西·迈耶博士
nextcure公司。
首席运营官
(240) 762-6486
IR@nextcure.com